These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38337073)

  • 1. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
    Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of
    Zhu W; Jia R; Yang Q; Cheng Y; Zhao H; Bai C; Xu J; Yao S; Huo L
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1613-1622. PubMed ID: 34874478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 4. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
    Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
    J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
    [No Abstract]   [Full Text] [Related]  

  • 5. Head-to-Head Comparison of
    Lin Z; Zhu W; Zhang J; Miao W; Yao S; Huo L
    J Nucl Med; 2023 Sep; 64(9):1406-1411. PubMed ID: 37474267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety, biodistribution, dosimetry of [
    Liu M; Ren C; Zhang H; Zhang Y; Huang Z; Jia R; Cheng Y; Bai C; Xu Q; Zhu W; Huo L
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3719-3730. PubMed ID: 38878175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
    Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin Receptor Antagonists for Imaging and Therapy.
    Fani M; Nicolas GP; Wild D
    J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution and radiation dose estimates for
    Krebs S; Pandit-Taskar N; Reidy D; Beattie BJ; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; O'Donoghue JA
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):677-685. PubMed ID: 30374529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
    Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
    J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Biodistribution, and Radiation Dosimetry of
    Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective head-to-head comparison of
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.